Remedent (Remedent) GF Value : $0.00 (As of May. 01, 2024)

View and export this data going back to 2000. Start your Free Trial

What is Remedent GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-01), Remedent's share price is $0.055. Remedent's GF Value is $0.00. Therefore, Remedent's Price-to-GF-Value for today is .

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Remedent is Not Valued.

Remedent (OTCPK:REMI) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Remedent's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	0.055	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Remedent GF Value Related Terms

Thank you for viewing the detailed overview of Remedent's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Remedent (Remedent) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Remedent Inc (OTCPK:REMI) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

Zuiderlaan 1-3, Box 8, Ghent, BEL, 9000

Website

https://www.remedent.com

Remedent Inc is a manufacturer of cosmetic dentistry products in Europe. The company is engaged in the research, development, and manufacturing of oral care and cosmetic dentistry products. It designs, develops, manufactures, and distributes cosmetic dentistry products, including a full line of professional dental products that are distributed in Europe, Asia, the Middle East, and the United States. The product line of the company includes SmileWise, the SmileMe mirror, and the Condor intra-oral 3D scanner.

Executives

Stuart Steinberg	10 percent owner	85 BELLEVUE AVENUE, RYE NY 10580
Marxe Austin W & Greenhouse David M	10 percent owner	C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Gruber & Mcbaine Capital Management Llc	10 percent owner	234 VAN NESS, STE 5, SAN FRANCISCO CA 94133
Stephen Farley Ross	director, officer: CFO; Secretary	XAVIER DE COCKLAAN 42 DEURLE C9 9831
Fred Kolsteeg	director	XAVIER DE COCKLAAN 42 DEURLE C9 9831
Acker Philippe Van	director	C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 9831 DEURLE C9 9831
Robin List	other: Former Officer and Director	XAVIER DE COCKLAAN 42 DEURLE C9 9831
Roger Leddington	officer: Sr VP & Head of US Marketing	C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 DEURLE C9 9831
Guy Devreese	director, officer: Chairman of the Board	XAVIER DE COCKLAAN 42 DEURLE C9 9831
Judd Darrin Hoffman	officer: VP Worldwide Sales/Operations	702A JUANITA AVENUE REDONDO BEACH CA 90277
Nv Lausha	10 percent owner	C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 9831 DEURLE C9 9831

Remedent (Remedent) Headlines

From GuruFocus

Making Money from Smiles

By Frank Lind Frank Lind • 05-26-2011